Jan 30 |
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
|
Jan 9 |
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
|
Dec 27 |
NeuroSense Therapeutics gets notice from Nasdaq
|
Dec 27 |
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
|
Dec 14 |
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
|
Dec 6 |
We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
|
Dec 5 |
NeuroSense ALS candidate meets key study goals
|
Dec 5 |
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
|
Dec 4 |
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
|
Nov 28 |
NeuroSense Therapeutics GAAP EPS of -$0.67
|